The European Commission has approved Rinvoq for active polyarticular juvenile idiopathic arthritis in children aged two and older, adding another patient population to AbbVie’s rapidly growing immunology franchise and introducing a weight-based oral solution for younger patients.
AbbVie will present full Phase 3 CERVINO data for etentamig after the BCMA bispecific produced a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.
AbbVie’s etentamig delivered a 74% response rate and reduced the risk of progression or death by 60% in the Phase 3 CERVINO trial. Its real competitive proposition, however, may be operational: monthly dosing after a single step-up dose could help move BCMA-directed T-cell therapy beyond specialist centres.
AbbVie’s Phase 3 CERVINO trial met both primary endpoints as etentamig achieved a 74% response rate and reduced progression or death risk by 60% in heavily pretreated multiple myeloma.
Cariprazine Depot clears its first clinical safety hurdle as Mapi targets a U.S. IND in 2026 and potential 2029 NDA. See what comes next.
RiboX Therapeutics has received clearance from the United States Food and Drug Administration to begin clinical testing of RXIM002, an experimental treatment designed to create temporary anti-CD19 CAR-T cells directly inside the body of a patient with autoimmune disease. The August 8, 2026 investigational new drug clearance allows RiboX Therapeutics to initiate the Phase 1
Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.
AbbVie has secured a broad pediatric label for Skyrizi, adding both plaque psoriasis and active psoriatic arthritis alongside a new dose for children weighing less than 40 kg. The approval could strengthen treatment choice, although the evidence supporting the two indications is not equally direct.
AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.